Lithium use and discontinuation in a health maintenance organization

American Journal of Psychiatry

Volumn 153, Issue 8, 1996, Pages 993-1000

  Johnson, Richard E ^a,b   McFarland, Bentson H ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM CARBONATE; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG USE; DRUG WITHDRAWAL; EMERGENCY HEALTH SERVICE; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MANIC DEPRESSIVE PSYCHOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029788785     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.8.993     Document Type: Article

References (41)

1. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Bipolar Disorder. Am J Psychiatry 1994; 151(Dec suppl)
2. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD: Efficacy of divalproex vs lithium and placebo in the treatment of mania: the Depakote Mania Study Group. JAMA 1994; 271:918-924; correction, 271: 1830
3. Price LH, Heninger GR: Lithium in the treatment of mood disorder. N Engl J Med 1994; 331:591-598
4. Goodwin FK, Jamison KR: Manic Depressive Illness. New York, Oxford University Press, 1990
5. Coppen A: Depression as a lethal disease: prevention strategies. J Clin Psychiatry 1994; 55(April suppl):37-45
6. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK: The de facto US mental and addictive disorders service system: Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50:85-94
7. Narrow WE, Regier DA, Rae DS, Manderscheid RW, Locke BZ: Use of services by persons with mental and addictive disorders: findings from the National Institute of Mental Health Epidemiologic Catchment Area program. Arch Gen Psychiatry 1993; 50: 95-107
8. Prien RF: Lithium therapy: epidemiological considerations, in Epidemiological Impact of Psychotropic Drugs. Edited by Tognoni G, Bellantuono C, Lader M. Amsterdam, Elsevier/North Holland, 1981, pp 237-248
9. Eastwood R, Stiasny S, Tice S: Estimates of the prevalence of bipolar affective disorder. Acta Psychiatr Scand 1981; 63:83-90
10. Reifman A, Wyatt RJ: Lithium: a brake in the rising cost of mental illness. Arch Gen Psychiatry 1980; 37:385-388
11. Escobar JI, Anthony JC, Canino G, Cottler L, Melville ML, Golding JM: Use of neuroleptics, antidepressants and lithium by US community populations. Psychopharmacol Bull 1987; 23: 196-200
12. Barker PR, Manderscheid RW, Hendershot GE, Jack SS, Schoenborn CA, Goldstrom I: Serious mental illness and disability in the adult household population: United States, 1989, in Mental Health, United States, 1992: DHHS Publication (SMA) 92-1942. Edited by Manderscheid RW, Sonnenschein MA. Washington, DC, US Government Printing Office, 1992, pp 255-268
13. Olfson M, Pincus HA: Outpatient psychotherapy in the United States, I: volume, costs, and user characteristics. Am J Psychiatry 1994; 151:1281-1288
14. Olfson M, Pincus HA: Outpatient psychotherapy in the United States, II: patterns of utilization. Am J Psychiatry 1994; 151: 1289-1294
15. McCreadie RG, Morrison DP: The impact of lithium in southwest Scotland, I: demographic and clinical findings. Br J Psychiatry 1985; 146:70-80
16. Kehoe RF, Mander AJ: Lithium treatment: prescribing and monitoring habits in hospital and general practice. BMJ 1992; 304:552-554
17. Vestergaard P, Schou M: Lithium treatment in Aarhus, 1: prevalence. Pharmacopsychiatry 1989; 22:99-100
18. Beardsley RS, Gardocki GJ, Larson DB, Hidalgo J: Prescribing of psychotropic medication by primary care physicians and psychiatrists. Arch Gen Psychiatry 1988; 45:1117-1119
19. Olfson M, Klerman GL: Trends in the prescription of psychotropic medications - the role of physician specialty. Med Care 1993;31:559-564
20. Jamison KR, Goodwin FK: Psychotherapeutic issues in bipolar illness, in Psychiatry Update: The American Psychiatric Association Annual Review, vol 2. Edited by Grinspoon L. Washington, DC, American Psychiatric Association, 1983, pp 319-345
21. Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M: Out-come after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993; 50:448-455
22. Suppes T, Baldessarini RJ, Faedda GL, Tohen M: Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48:1082-1088
23. Mander AJ, Loudon JB: Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet 1988; 2:15-17
24. Vestergaard P, Amdisen A, Schou M: Clinically significant side effects of lithium treatment: a survey of 237 patients in long-term treatment. Acta Psychiatr Scand 1980; 62:193-200
25. Escalante D, Mallette LE: Medical complications of lithium therapy. Drug Therapy, Sept 1992, pp 59-77
26. Joint Formulary Committee: British National Formulary 22. London, British Medical Association/Pharmaceutical Society of Great Britain, 1991
27. Loudon JB: Drug treatment, in Companion to Psychiatric Studies, 4th ed. Edited by Kendall RE, Zeally AK. Edinburgh, Churchill Livingstone, 1988, pp 682-708
28. McFarland BH: Health maintenance organizations and persons with severe mental illness. Community Ment Health J 1994; 30: 221-242
29. Johnson RE, McFarland BH: Treated prevalence rates of severe mental illness among HMO members. Hosp Community Psychiatry 1994; 45:919-924
30. Group Health Association of America: HMO Industry Profile: 1994 Edition. Washington, DC, GHAA, 1994
31. Open minds: almost half of insured Americans enrolled in behavioral managed care. Hosp Community Psychiatry 1994; 45:944
32. Sernyak MJ, Griffin RA, Johnson RM, Pearsall HR, Wexler BE, Woods SW: Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. Am J Psychiatry 1994; 151:133-135
33. Sernyak MH, Woods SW: Chronic neuroleptic use in manic depressive illness. Psychopharmacol Bull 1993; 29:375-381
34. Van Putten T: Why do patients with manic-depressive illness stop their lithium? Compr Psychiatry 1975; 16:179-183
35. Jamison KR, Akiskal HS: Medication compliance in patients with bipolar disorder. Psychiatr Clin North Am 1983; 6:175-192
36. Millett K: The Loony-Bin Trip. New York, Simon & Schuster, 1990
37. Himmelhoch JM: On the failure to recognize lithium failure. Psychiatr Annals 1994; 24:241-250
38. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, Lavelle J: Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321:1489-1493
39. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM: The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994; 31: 281-294
40. Wells KB, Hays RD, Burnam MA, Rogers W, Greenfield S, Ware JE Jr: Detection of depressive disorder for patients receiving prepaid or fee-for-service care: results from the Medical Outcomes Study. JAMA 1989; 262:3298-3302
41. Rogers WH, Wells KB, Meredith LS, Sturm R, Burnam MA: Outcomes for adult outpatients with depression under prepaid or fee-for-service financing. Arch Gen Psychiatry 1993; 50:517-525